Blood glucose and insulin management
Mangiferin inhibits intestinal alpha-glucosidase and alpha-amylase enzymes — slowing carbohydrate digestion and reducing postprandial glucose spikes. Additionally, mangiferin activates AMPK (the cellular energy sensor) in muscle and liver cells, improving glucose uptake and insulin sensitivity through mechanisms similar to metformin but from a natural botanical source.
Anti-inflammatory and antioxidant protection
Mangiferin's C-glucosylxanthone structure provides exceptional free radical scavenging activity and NF-κB pathway inhibition — reducing pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β) that drives chronic metabolic inflammation. This anti-inflammatory activity complements and amplifies the blood sugar benefits by reducing the inflammation that impairs insulin receptor signaling.
Lipid profile and cardiovascular support
Clinical and preclinical studies confirm mangiferin supplementation improves lipid profiles — reducing total cholesterol, LDL, and triglycerides while modestly increasing HDL. These cardiovascular benefits, combined with improved insulin sensitivity and reduced oxidative stress, position Melostacio® as a comprehensive metabolic health ingredient.
AMPK activation and alpha-glucosidase inhibition
Mangiferin activates AMP-activated protein kinase (AMPK) by increasing the AMP:ATP ratio in metabolic tissues — triggering glucose transporter GLUT4 translocation to cell membranes for improved glucose uptake independent of insulin signaling. Simultaneously, mangiferin competitively inhibits intestinal alpha-glucosidase, reducing the rate of carbohydrate digestion and glucose absorption. The dual mechanism (improved peripheral glucose uptake + reduced glucose absorption) addresses blood sugar from both directions.
Randomized, double-blind, placebo-controlled trial of mangiferin supplementation in type 2 diabetic patients over 12 weeks.
Type 2 diabetic patients. 12-week RCT.
Mangiferin supplementation significantly reduced fasting blood glucose, HbA1c, and postprandial glucose vs. placebo. Lipid profiles improved (reduced LDL, triglycerides). Inflammatory markers reduced. Well-tolerated with no serious adverse events. Supports mangiferin/Melostacio® for metabolic health applications.